311 related articles for article (PubMed ID: 26061179)
1. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.
Tang JL; Kung HC; Lei WC; Yao M; Wu UI; Hsu SC; Lin CT; Li CC; Wu SJ; Hou HA; Chou WC; Huang SY; Tsay W; Chen YC; Chen YC; Chang SC; Ko BS; Tien HF
PLoS One; 2015; 10(6):e0128410. PubMed ID: 26061179
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study.
Lien MY; Chou CH; Lin CC; Bai LY; Chiu CF; Yeh SP; Ho MW
PLoS One; 2018; 13(6):e0197851. PubMed ID: 29883443
[TBL] [Abstract][Full Text] [Related]
4. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.
Gomes MZ; Mulanovich VE; Jiang Y; Lewis RE; Kontoyiannis DP
Antimicrob Agents Chemother; 2014; 58(2):865-73. PubMed ID: 24277033
[TBL] [Abstract][Full Text] [Related]
5. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
[TBL] [Abstract][Full Text] [Related]
7. Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.
Pagano L; Verga L; Busca A; Martino B; Mitra ME; Fanci R; Ballanti S; Picardi M; Castagnola C; Cattaneo C; Nadali G; Nosari A; Candoni A; Caira M; Salutari P; Lessi F; Aversa F; Tumbarello M
J Antimicrob Chemother; 2014 Nov; 69(11):3142-7. PubMed ID: 24948702
[TBL] [Abstract][Full Text] [Related]
8. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
9. Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia.
Devanlay C; Tavernier-Tardy E; Bourmaud A; Falk AT; Raberin H; Menguy S; Guyotat D; Magné N; Cornillon J
Biomed J; 2015; 38(3):235-43. PubMed ID: 25355388
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis.
Signorelli J; Lei M; Lam J; Jalbut M; Amrein PC; Fathi AT; Hobbs G; Hock H; McAfee SL; Letourneau AR; Narayan R; Brunner A
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e883-e889. PubMed ID: 32917574
[TBL] [Abstract][Full Text] [Related]
11. Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach.
Martino R; Garrido A; Santaliestra M; García-Cadenas I; Novelli S; Saavedra SD; Esquirol A; Granell M; Briones J; Moreno C; Brunet S; Giménez A; Hidalgo A; Sánchez F; Sierra J
Mycopathologia; 2020 Aug; 185(4):639-652. PubMed ID: 32564177
[TBL] [Abstract][Full Text] [Related]
12. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
13. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
14. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis.
Sezgin Evim M; Tüfekçi Ö; Baytan B; Ören H; Çelebi S; Ener B; Üstün Elmas K; Yılmaz Ş; Erdem M; Hacımustafaoğlu MK; Güneş AM
Turk J Haematol; 2022 Jun; 39(2):94-102. PubMed ID: 34792308
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and outcome of invasive fungal infections in pediatric acute myeloid leukemia patients in a medical center in Taiwan.
Lin GL; Chang HH; Lu CY; Chen CM; Lu MY; Lee PI; Jou ST; Yang YL; Huang LM; Chang LY
J Microbiol Immunol Infect; 2018 Apr; 51(2):251-259. PubMed ID: 28089099
[TBL] [Abstract][Full Text] [Related]
16. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.
Nganthavee V; Phutthasakda W; Atipas K; Tanpong S; Pungprasert T; Dhirachaikulpanich D; Krithin S; Tanglitanon S; Jutidamronphang W; Owattanapanich W; Chayakulkeeree M; Phikulsod P
Support Care Cancer; 2019 Sep; 27(9):3613-3622. PubMed ID: 31165931
[TBL] [Abstract][Full Text] [Related]
17. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.
Michallet M; Sobh M; Morisset S; Deloire A; Raffoux E; de Botton S; Caillot D; Chantepie S; Girault S; Berthon C; Bertoli S; Lepretre S; Leguay T; Castaigne S; Marolleau JP; Pautas C; Malfuson JV; Veyn N; Braun T; Gastaud L; Suarez F; Schmidt A; Gressin R; Bonmati C; Celli-Lebras K; El-Hamri M; Ribaud P; Dombret H; Thomas X; Bergeron A
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):311-318. PubMed ID: 34895843
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
19. Invasive fungal infection following chemotherapy for acute myeloid leukaemia-Experience from a developing country.
Korula A; Abraham A; Abubacker FN; Viswabandya A; Lakshmi KM; Abraham OC; Rupali P; Varghese GM; Michael JS; Srivastava A; Mathews V; George B
Mycoses; 2017 Oct; 60(10):686-691. PubMed ID: 28736936
[TBL] [Abstract][Full Text] [Related]
20. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Wang L; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Medicine (Baltimore); 2016 Jan; 95(4):e2560. PubMed ID: 26825897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
